LYT-200 is being advanced in hematological malignancies such as acute myeloid leukemia and high-risk myelodysplastic syndrome , and locally advanced/metastatic solid tumors, including head and neck.
PureTech Health PLC on Wednesday touted the efficacy of its acute myeloid leukaemia therapy, after securing a regulatory designation from the US Food & Drug Administration.
According to the Boston,.
The Food and Drug Administration approved Tibsovo for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation.